An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening

Fatima Amanat; Kris M. White; Lisa Miorin; Shirin Strohmeier; Meagan McMahon; Philip Meade; Wen Chun Liu; Randy A. Albrecht; Viviana Simon; Luis Martinez-Sobrido; Thomas Moran; Adolfo García-Sastre; Florian Krammer

doi:10.1002/cpmc.108

An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening

Fatima Amanat, Kris M. White, Lisa Miorin, Shirin Strohmeier, Meagan McMahon, Philip Meade, Wen Chun Liu, Randy A. Albrecht, Viviana Simon, Luis Martinez-Sobrido, Thomas Moran, Adolfo García-Sastre, Florian Krammer

Research output: Contribution to journal › Article › peer-review

122 Scopus citations

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in the city of Wuhan, Hubei Province, China, in late 2019. Since then, the virus has spread globally and caused a pandemic. Assays that can measure the antiviral activity of antibodies or antiviral compounds are needed for SARS-CoV-2 vaccine and drug development. Here, we describe in detail a microneutralization assay, which can be used to assess in a quantitative manner if antibodies or drugs can block entry and/or replication of SARS-CoV-2 in vitro.

Original language	English
Article number	e108
Journal	Current Protocols in Microbiology
Volume	58
Issue number	1
DOIs	https://doi.org/10.1002/cpmc.108
State	Published - 1 Sep 2020

Keywords

COVID-19
COVID19
SARS-CoV-2
antivirals
medium-throughput screening
microneutralization
neutralization

Access to Document

10.1002/cpmc.108

Cite this

@article{f88b11e5b6d64aa2bff91caed5aa7e17,

title = "An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening",

abstract = "The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in the city of Wuhan, Hubei Province, China, in late 2019. Since then, the virus has spread globally and caused a pandemic. Assays that can measure the antiviral activity of antibodies or antiviral compounds are needed for SARS-CoV-2 vaccine and drug development. Here, we describe in detail a microneutralization assay, which can be used to assess in a quantitative manner if antibodies or drugs can block entry and/or replication of SARS-CoV-2 in vitro.",

keywords = "COVID-19, COVID19, SARS-CoV-2, antivirals, medium-throughput screening, microneutralization, neutralization",

author = "Fatima Amanat and White, {Kris M.} and Lisa Miorin and Shirin Strohmeier and Meagan McMahon and Philip Meade and Liu, {Wen Chun} and Albrecht, {Randy A.} and Viviana Simon and Luis Martinez-Sobrido and Thomas Moran and Adolfo Garc{\'i}a-Sastre and Florian Krammer",

note = "Publisher Copyright: {\textcopyright} 2020 Wiley Periodicals LLC",

year = "2020",

month = sep,

day = "1",

doi = "10.1002/cpmc.108",

language = "English",

volume = "58",

journal = "Current Protocols in Microbiology",

issn = "1934-8525",

publisher = "John Wiley & Sons Inc.",

number = "1",

}

TY - JOUR

T1 - An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening

AU - Amanat, Fatima

AU - White, Kris M.

AU - Miorin, Lisa

AU - Strohmeier, Shirin

AU - McMahon, Meagan

AU - Meade, Philip

AU - Liu, Wen Chun

AU - Albrecht, Randy A.

AU - Simon, Viviana

AU - Martinez-Sobrido, Luis

AU - Moran, Thomas

AU - García-Sastre, Adolfo

AU - Krammer, Florian

PY - 2020/9/1

Y1 - 2020/9/1

N2 - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in the city of Wuhan, Hubei Province, China, in late 2019. Since then, the virus has spread globally and caused a pandemic. Assays that can measure the antiviral activity of antibodies or antiviral compounds are needed for SARS-CoV-2 vaccine and drug development. Here, we describe in detail a microneutralization assay, which can be used to assess in a quantitative manner if antibodies or drugs can block entry and/or replication of SARS-CoV-2 in vitro.

AB - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in the city of Wuhan, Hubei Province, China, in late 2019. Since then, the virus has spread globally and caused a pandemic. Assays that can measure the antiviral activity of antibodies or antiviral compounds are needed for SARS-CoV-2 vaccine and drug development. Here, we describe in detail a microneutralization assay, which can be used to assess in a quantitative manner if antibodies or drugs can block entry and/or replication of SARS-CoV-2 in vitro.

KW - COVID-19

KW - COVID19

KW - SARS-CoV-2

KW - antivirals

KW - medium-throughput screening

KW - microneutralization

KW - neutralization

UR - http://www.scopus.com/inward/record.url?scp=85087099748&partnerID=8YFLogxK

U2 - 10.1002/cpmc.108

DO - 10.1002/cpmc.108

M3 - Article

C2 - 32585083

AN - SCOPUS:85087099748

SN - 1934-8525

VL - 58

JO - Current Protocols in Microbiology

JF - Current Protocols in Microbiology

IS - 1

M1 - e108

ER -

An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening

Abstract

Keywords

Access to Document

Fingerprint

Cite this